-transparent.png){kind=logo}
The role of hepatic drug-metabolizing enzyme activity for plasma propranolol and sotalol levels was investigated in 68 patients with hypertension or angina pectoris by comparing elimination rate with antipyrine kinetics and cytochrome P-450 content in the liver. All subjects were resistant to or had hepatotoxic reaction to previous treatment. Plasma antipyrine clearance and cytochrome P-450 content in biopsies were related to propranolol elimination from plasma, the best fit being obtained with the clearance values. Sotalol plasma clearance was not related to any indirect or direct reflector of the hepatic drug-metabolizing enzyme system. The results demonstrate that plasma clearance of the short-acting beta blocker, propranolol, depends on the activity of hepatic drug-metabolizing enzyme system and indicates a trial with a drug such as sotalol which is not dependent on liver metabolizing capacity.
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
January 2003,
Acta physiologica Hungarica,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
December 2008,
Clinical pharmacology and therapeutics,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
April 1974,
Xenobiotica; the fate of foreign compounds in biological systems,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
June 1977,
European journal of pharmacology,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
January 1988,
Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
January 1979,
Pharmacology,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
April 1984,
Prostaglandins, leukotrienes, and medicine,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
July 1982,
The Journal of pharmacy and pharmacology,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
April 1974,
Pharmacological research communications,
E A Sotaniemi, and
M Anttila, and
R O Pelkonen, and
P Järvensivu, and
H Sundquist
September 2018,
Nuclear medicine communications,
